期刊文献+

依达拉奉(MCI-186)治疗急性脑梗死的临床观察 被引量:6

Clinical Evaluati of Edaravone for Acute Cerebral Infarction
在线阅读 下载PDF
导出
摘要 目的:观察依达拉奉(MCI 186)治疗急性脑梗死(ACI)的临床疗效。方法:选择发病72 h内的ACI患者72 例,随机分为依达拉奉治疗组33例和对照组39例。治疗组应用依达拉奉静脉给药,剂量为30mg,2次/d,共计14d,余治疗与对照组相同。治疗前后对患者进行改良爱丁堡斯堪的那维亚量表(SSS)及日常生活能力(ADL)的测定。结果:治疗14 d后,治疗组SSS由治疗前的(20.83±11.36)下降到治疗后的(7.83±8.72),具有显著差异(p<0.01);对照组SSS由治疗前的(21.56±10.27)下降到治疗后的(12.56±7.36),具有显著差异(p<0.05);两组治疗后相比具有显著差异(p<0.05)。治疗组ADL由治疗前的(35.36±23.45)上升到治疗后的(68.46±28.43),具有显著差异,(p<0.01);对照组ADL由治疗前的(33.53±20.70)上升到治疗后的(52.72±24.81),具有显著差异,(p<0.01);两组治疗后相比具有显著差异(p<0.05)。治疗组无不良反应。结论:依达拉奉治疗急性脑梗死安全有效。 Objective:To investigate the effects of Edaravone on acute cerebral infarction. Methods: 72 cases of acute cerebral infarction (ACI), enrolled within 72h of onset, were randomly divided into the Edaravone group (33 cases) and control group (39 cases). Edaravone was infused at a dose of 30mg, twice a day, for 14 days. The therapies of the control group were similar to those of Edaravone group except for Edaravone. We assessed Scandinavian Stroke Scale (SSS) and activities of daily living (ADL) before and after treatment. Results: After 14 th day treatment, there was a significant difference of SSS score between pre-cure Edaravone group ( 20.83± 11.36)and post-cure Edaravone group( 7.83± 8.72)(p< 0.01), there was a significant difference of SSS score between pre-cure control group ( 21.56± 10.27)and post-cure control group( 12.56± 7.36)(p< 0.05),the SSS score of post-cure Edaravone group was significantly lower than that of control group(p< 0.05). There was a significant difference of ADL score between pre-cure Edaravone group (35.36±23.45)and post-cure Edaravone group( 68.46± 28.43)(p< 0.01), there was a significant difference of ADL score between pre-cure control group( 33.53± 20.70)and post-cure control group( 52.72± 24.81)(p< 0.01),the ADL score of post-cure Edaravone group was significantly higher than that of control group(p< 0.05). There was no distinct adverse reaction in Edaravone group. Conclusion:Edaravone was an effective and safe medicine in the treatment of acute cerebral infarction.
出处 《中国临床医学》 北大核心 2005年第2期340-341,共2页 Chinese Journal of Clinical Medicine
  • 相关文献

参考文献8

  • 1脑血管疾病分类(1995)(中、英文)[J].中华神经科杂志,1996,29(6):376-378. 被引量:430
  • 2Toyoda T, Kassell NF, Lec KS. Attenuation of ischemia-reperfusion injury in the rat neocortex by the hydroxyl radical seavenger incavavan[J]. Neurosurgery, 1997,40 : 372-378.
  • 3Schwab S, Schwarz S, et al, Moderate hypothermia and brain temperature in patients with severe middle cerebral artery infarction[J]. Acta Neurochidr Suppl (Wien) 1998,71 : 131-134.
  • 4Yamamoto T, Yuki S, Watanbe T, et al. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in transient cerebral ischemia[J]. J Brain Res, 1997,762:240.
  • 5Tomoaki K, Xia YX, Masatokik, et al. Effect of the free radical scavenger 3-methyl-1-phenyl-2- pyrazolin-5-one (MCI-186) on hypoxia-is-chemia-indurced brain injury in neonatal rats Neurosci[J]. Lett, 2002,329: 33.
  • 6Kozue S, Yukio I, Seiji S, et al. Edaravone scavengers nitric oxide Redox[J]. Report, 2002,7 : 219.
  • 7Eiichi O, Effect of a novel free radical scavengers Edaravone (MCI-186) on Acute brain infarction[J]. Cerebrovase Dis, 2002,7:219.
  • 8Tanaka M. Pharmacological and clinical profile of free radical scavenger edaravone as a neuroprotective agent [J]. Nippon Yakurigaku Zasshi, 2002,119: 301-308.

共引文献429

同被引文献50

引证文献6

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部